Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Cognition Therapeutics Regains Compliance: Cognition Therapeutics, Inc. has regained compliance with Nasdaq's minimum share price requirement after its stock maintained a closing bid price of $1.00 or more for 10 consecutive business days as of August 25, 2025.
Ongoing Clinical Trials: The company is advancing its lead candidate, zervimesine (CT1812), through Phase 2 studies targeting neurodegenerative disorders, including dementia with Lewy bodies and Alzheimer's disease, supported by significant funding from the National Institute of Aging.
Trade with 70% Backtested Accuracy
Analyst Views on CGTX
About CGTX
About the author
Cognition Extends Expanded Access Program for DLB
- Extended Access Program Duration: Cognition Therapeutics has announced an extension of the treatment duration for its Expanded Access Program (EAP) for dementia with Lewy bodies (DLB) from the original twelve months to several additional months, aimed at gathering more long-term safety data to enhance the reliability of clinical research.
- Positive Patient Feedback: Since its launch in June 2025, the program has enrolled 32 participants, who have provided favorable feedback regarding their treatment experience, indicating strong recognition from patients and their caregivers, which may facilitate future patient recruitment.
- Local Physician Involvement: By empowering local physicians to conduct routine health monitoring and allowing local laboratory testing, Cognition has effectively reduced travel burdens for patients, a strategy that not only enhances patient convenience but may also improve adherence and satisfaction levels among participants.
- FDA Meeting Progress: Cognition held a meeting with the FDA on January 21, 2026, to discuss findings from the SHIMMER study and clinically meaningful endpoints for future research, with meeting minutes expected in February, which will provide crucial guidance for subsequent studies.
Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.
Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.
Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.
Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.
Biotech and Healthcare Stocks Top After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO
Biotech Gains in After-Hours Trading: Several small- and mid-cap biotech and healthcare companies saw significant gains in after-hours trading, driven by corporate updates and financing developments.
SeaStar Medical's Leadership Change: SeaStar Medical's stock rose nearly 10% after the appointment of Michael Messinger as Chief Financial Officer, boosting investor confidence despite no new news.
Cognition Therapeutics' Speculative Buying: Cognition Therapeutics rebounded almost 11% in after-hours trading, likely due to speculative buying interest, following a decline during regular trading hours.
Mesoblast's Revenue Projection: Mesoblast's shares increased after management projected over $30 million in gross revenue for the December quarter, indicating strong demand for its cell therapy product, Ryoncil.
HC Wainwright & Co. Affirms Buy Rating for Cognition Therapeutics, Keeps $3 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
Cognition Therapeutics Finishes Participant Enrollment for Phase 2 Trial of Zervimesine (CT1812) in Early Alzheimer's Disease
Cognition Therapeutics' START Study Enrollment: Cognition Therapeutics has successfully enrolled 540 participants in its Phase 2 START Study, which evaluates the safety and efficacy of zervimesine (CT1812) for treating mild cognitive impairment and early Alzheimer's disease, with results expected after 18 months of treatment.
Collaboration and Support: The study is supported by an $81 million grant from the National Institute of Aging and conducted in partnership with the Alzheimer's Clinical Trials Consortium, highlighting the collaborative effort in Alzheimer's research.
Zervimesine's Unique Mechanism: Zervimesine is an investigational oral drug that targets neurodegenerative diseases by potentially interrupting the toxic effects of harmful proteins in the brain, offering a new treatment avenue for patients who do not respond to existing therapies.
Future Implications for Alzheimer's Treatment: The study aims to explore zervimesine's role in combination therapy for patients already receiving approved monoclonal antibody treatments, potentially expanding treatment options for a broader range of Alzheimer's patients.
CGTX, RVPH, SHOT, SONN, AKTX Surge in After-Hours Trading Following Clinical Developments and Fed Rate Cut Expectations
Biotech Sector Response to Economic Changes: Biotech and healthcare stocks are reacting positively to the Federal Reserve's first rate cut of 2025, which is expected to improve funding conditions for capital-intensive sectors like biotechnology. Companies are experiencing notable price movements due to clinical trial progress and regulatory developments.
Sonnet BioTherapeutics Update: Sonnet BioTherapeutics' shares rose significantly after announcing expanded clinical evaluation of its lead candidate for ovarian cancer, along with a strong safety profile and partial response results. Key upcoming events include a stockholder meeting and trial updates.
Akari Therapeutics Patent Filing: Akari Therapeutics saw a surge in its stock price following a provisional patent filing for its antibody-drug conjugate platform aimed at cancer treatment, which enhances its intellectual property and supports the development of innovative therapies.
Reviva Pharmaceuticals and Cognition Therapeutics Developments: Reviva Pharmaceuticals' stock increased after a revised analyst rating maintained confidence in its long-term potential, while Cognition Therapeutics announced a $30 million offering to support its Alzheimer's treatment candidate, Zervimesine, which is progressing towards Phase 3 development.
Cognition Extends Expanded Access Program for DLB
- Extended Access Program Duration: Cognition Therapeutics has announced an extension of the treatment duration for its Expanded Access Program (EAP) for dementia with Lewy bodies (DLB) from the original twelve months to several additional months, aimed at gathering more long-term safety data to enhance the reliability of clinical research.
- Positive Patient Feedback: Since its launch in June 2025, the program has enrolled 32 participants, who have provided favorable feedback regarding their treatment experience, indicating strong recognition from patients and their caregivers, which may facilitate future patient recruitment.
- Local Physician Involvement: By empowering local physicians to conduct routine health monitoring and allowing local laboratory testing, Cognition has effectively reduced travel burdens for patients, a strategy that not only enhances patient convenience but may also improve adherence and satisfaction levels among participants.
- FDA Meeting Progress: Cognition held a meeting with the FDA on January 21, 2026, to discuss findings from the SHIMMER study and clinically meaningful endpoints for future research, with meeting minutes expected in February, which will provide crucial guidance for subsequent studies.
Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.
Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.
Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.
Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.
Biotech and Healthcare Stocks Top After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO
Biotech Gains in After-Hours Trading: Several small- and mid-cap biotech and healthcare companies saw significant gains in after-hours trading, driven by corporate updates and financing developments.
SeaStar Medical's Leadership Change: SeaStar Medical's stock rose nearly 10% after the appointment of Michael Messinger as Chief Financial Officer, boosting investor confidence despite no new news.
Cognition Therapeutics' Speculative Buying: Cognition Therapeutics rebounded almost 11% in after-hours trading, likely due to speculative buying interest, following a decline during regular trading hours.
Mesoblast's Revenue Projection: Mesoblast's shares increased after management projected over $30 million in gross revenue for the December quarter, indicating strong demand for its cell therapy product, Ryoncil.
HC Wainwright & Co. Affirms Buy Rating for Cognition Therapeutics, Keeps $3 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
Cognition Therapeutics Finishes Participant Enrollment for Phase 2 Trial of Zervimesine (CT1812) in Early Alzheimer's Disease
Cognition Therapeutics' START Study Enrollment: Cognition Therapeutics has successfully enrolled 540 participants in its Phase 2 START Study, which evaluates the safety and efficacy of zervimesine (CT1812) for treating mild cognitive impairment and early Alzheimer's disease, with results expected after 18 months of treatment.
Collaboration and Support: The study is supported by an $81 million grant from the National Institute of Aging and conducted in partnership with the Alzheimer's Clinical Trials Consortium, highlighting the collaborative effort in Alzheimer's research.
Zervimesine's Unique Mechanism: Zervimesine is an investigational oral drug that targets neurodegenerative diseases by potentially interrupting the toxic effects of harmful proteins in the brain, offering a new treatment avenue for patients who do not respond to existing therapies.
Future Implications for Alzheimer's Treatment: The study aims to explore zervimesine's role in combination therapy for patients already receiving approved monoclonal antibody treatments, potentially expanding treatment options for a broader range of Alzheimer's patients.
CGTX, RVPH, SHOT, SONN, AKTX Surge in After-Hours Trading Following Clinical Developments and Fed Rate Cut Expectations
Biotech Sector Response to Economic Changes: Biotech and healthcare stocks are reacting positively to the Federal Reserve's first rate cut of 2025, which is expected to improve funding conditions for capital-intensive sectors like biotechnology. Companies are experiencing notable price movements due to clinical trial progress and regulatory developments.
Sonnet BioTherapeutics Update: Sonnet BioTherapeutics' shares rose significantly after announcing expanded clinical evaluation of its lead candidate for ovarian cancer, along with a strong safety profile and partial response results. Key upcoming events include a stockholder meeting and trial updates.
Akari Therapeutics Patent Filing: Akari Therapeutics saw a surge in its stock price following a provisional patent filing for its antibody-drug conjugate platform aimed at cancer treatment, which enhances its intellectual property and supports the development of innovative therapies.
Reviva Pharmaceuticals and Cognition Therapeutics Developments: Reviva Pharmaceuticals' stock increased after a revised analyst rating maintained confidence in its long-term potential, while Cognition Therapeutics announced a $30 million offering to support its Alzheimer's treatment candidate, Zervimesine, which is progressing towards Phase 3 development.
